Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

g statements," including statements relating to Lexicon's clinical development of LX1033, characterizations of the results of and projected timing of clinical trials of LX1033, and the potential therapeutic and commercial potential of LX1033.  The press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/23/2014)... New York, New York (PRWEB) August 23, 2014 ... ( http://www.consumerinjurylawyers.com/wright-conserve-hip-replacement.html ) filed on behalf of ... in the Conserve hip replacement line continue to ... District of Georgia, Bernstein Liebhard LLP reports. According ... has established a bellwether trial program that would ...
(Date:8/23/2014)... NY (PRWEB) August 23, 2014 On ... reported on a data breach suffered by Community ... saw the compromise of 4.5 million records containing Personally ... security numbers. According to Mandiant, who was engaged to ... from an advanced group of cyber attackers based ...
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Dealing with a drug or alcohol substance abuse is never ... child. Adolescent addiction has been an important issue among young ... helpline is now providing a valuable resource for teenage ... addiction recovery center. , The Troubled Teens Atlanta helpline was ... By calling (404) 975-2762, parents and their teens can speak ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2
... cancer are at higher risk of developing diabetes or diabetes ... block the production or action of male hormones that can ... new study on the second-most common cancer in men are ... in Boston. "These patients may benefit from counseling, screening ...
... (Hamilton, ON) June 4, 2011 - Additional radiation treatment ... recurring in women with early breast cancer who have ... new study found. The results will be presented Monday, ... Society of Clinical Oncology. "These results are ...
... a lot of sugar to stay alive. In fact, where normal, ... of oxygen, cancerous cells use virtually no oxygen and a lot ... now, reporting in the May 27 issue of Cell , ... that this so-called Warburg effect is controlled. "It turns ...
... -- ASCO Abstract #10504. Contrary to what many oncologists had ... reduce the effectiveness of the breast cancer drug Herceptin, according ... North Central Cancer Research Group (NCCTG) investigators. The study, ... NCCTG N9831 clinical trial, found that patients with HER2-positive breast ...
... is the most lethal type of skin cancer, the results of ... immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. ... June 2 issue of New England Journal of Medicine . ... one of the first in all cancers to show clinical benefit ...
... Amanda Gardner HealthDay Reporter , THURSDAY, June ... used to treat high blood pressure doesn,t boost the ... health authorities announced Thursday. The drugs are known ... telmisartan (Micardis), losartan (Cozaar), valsartan (Diovan) and candesartan (Atacand). ...
Cached Medicine News:Health News:Hormone deprivation therapy for prostate cancer may raise diabetes risk 2Health News:Breast cancer surgery patients benefit from adding radiation therapy 2Health News:Understanding cancer energetics 2Health News:Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drug 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 3Health News:Popular Blood Pressure Meds Not Linked to Cancer, FDA Says 2
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: